CARBIDOPA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Carbidopa, and when can generic versions of Carbidopa launch?
Carbidopa is a drug marketed by Alvogen, Ani Pharms, Aurobindo Pharma, Beximco Pharms Usa, Edenbridge Pharms, Novel Labs Inc, Zydus Pharms, Accord Hlthcare, Alembic, Apotex, Impax Labs, Kv Pharm, Mylan, Sciegen Pharms Inc, Sun Pharm Inds, Rising, Sun Pharm, Actavis Elizabeth, Apotex Inc, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Rubicon, SCS, Watson Labs, and Wockhardt Ltd. and is included in thirty-nine NDAs.
The generic ingredient in CARBIDOPA is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.
Summary for CARBIDOPA
US Patents: | 0 |
Applicants: | 25 |
NDAs: | 39 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 78 |
Clinical Trials: | 207 |
Patent Applications: | 4,684 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CARBIDOPA |
What excipients (inactive ingredients) are in CARBIDOPA? | CARBIDOPA excipients list |
DailyMed Link: | CARBIDOPA at DailyMed |
Recent Clinical Trials for CARBIDOPA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bronx VA Medical Center | Phase 1 |
VistaGen Therapeutics, Inc. | Phase 2 |
University of Minnesota | Early Phase 1 |